{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fina E"],"funding":["Associazione Italiana per la Ricerca sul Cancro","Fondazione Umberto Veronesi","Fondazione Italiana per la Ricerca sul Cancro"],"pagination":["78"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8876758"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["41(1)"],"pubmed_abstract":["<h4>Background</h4>Progression to stage IV disease remains the main cause of breast cancer-related deaths. Increasing knowledge on the hematogenous phase of metastasis is key for exploiting the entire window of opportunity to interfere with early dissemination and to achieve a more effective disease control. Recent evidence suggests that circulating tumor cells (CTCs) possess diverse adaptive mechanisms to survive in blood and eventually metastasize, encouraging research into CTC-directed therapies.<h4>Methods</h4>On the hypothesis that the distinguishing molecular features of CTCs reveal useful information on metastasis biology and disease outcome, we compared the transcriptome of CTCs, primary tumors, lymph-node and lung metastases of the MDA-MB-231 xenograft model, and assessed the biol"],"journal":["Journal of experimental & clinical cancer research : CR"],"pubmed_title":["Gene signatures of circulating breast cancer cell models are a source of novel molecular determinants of metastasis and improve circulating tumor cell detection in patients."],"pmcid":["PMC8876758"],"funding_grant_id":["IG 16900","Fellowship 16411","Postdoctoral fellowships"],"pubmed_authors":["Ciniselli CM","Fina E","Lecchi M","Bianchi GV","Verderio P","Dugo M","Cleris L","Daidone MG","Cappelletti V","Lecis D"],"additional_accession":[]},"is_claimable":false,"name":"Gene signatures of circulating breast cancer cell models are a source of novel molecular determinants of metastasis and improve circulating tumor cell detection in patients.","description":"<h4>Background</h4>Progression to stage IV disease remains the main cause of breast cancer-related deaths. Increasing knowledge on the hematogenous phase of metastasis is key for exploiting the entire window of opportunity to interfere with early dissemination and to achieve a more effective disease control. Recent evidence suggests that circulating tumor cells (CTCs) possess diverse adaptive mechanisms to survive in blood and eventually metastasize, encouraging research into CTC-directed therapies.<h4>Methods</h4>On the hypothesis that the distinguishing molecular features of CTCs reveal useful information on metastasis biology and disease outcome, we compared the transcriptome of CTCs, primary tumors, lymph-node and lung metastases of the MDA-MB-231 xenograft model, and assessed the biol","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2026-04-08T17:21:32.859Z","creation":"2025-04-04T23:29:46.378Z"},"accession":"S-EPMC8876758","cross_references":{"pubmed":["35216615"],"doi":["10.1186/s13046-022-02259-8"]}}